"Alzheimer's drug market could swell to as much as $20 billion"
And Astex is in the middle of this exciting market with their partnered drug AZD3293.
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients
This study is currently recruiting participants.
Verified March 2013 by AstraZeneca
Information provided by (Responsible Party):
First received: February 18, 2013
Last updated: March 22, 2013
Last verified: March 2013
You left this out:
Estimated Enrollment: 56
Study Start Date: March 2013
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
They've been recuiting for three months but they have not filed an update. Have they actually recruited anyone and if so when is dosing supposed to start?